T
he results of the PARTNER 2 (Placement of Aortic Transcatheter Valves) and the SURTAVI (Surgical Replacement and Transcatheter Aortic Valve Implantation) trials have led to the expansion of the indication for transcatheter aortic valve replacement (TAVR) to patients with severe symptomatic aortic stenosis who are at intermediate surgical risk. [1] [2] [3] Although TAVR has become increasingly more accepted for management of severe aortic stenosis, surgical AVR (SAVR) has demonstrated promising results as well with a subanalysis of SAVR patients from the PARTNER 2A trial showing operative mortality of only 4.2%. 4 These large trials suggest that as we expand our studies to compare TAVR and SAVR in patients at low surgical risk, it may be extremely difficult to distinguish these 2 groups on the basis of mortality alone. 5, 6 As such, evaluation of the 2 procedures based on health care resource utilization, such as length of stay (LOS) and discharge disposition will become essential. More specifically, hospital LOS becomes an ever more crucial variable in the management of TAVR patients as health care systems move towards bundled fixed payment system. 7 Additionally, home discharge after valve surgery remains of utmost importance as it has been associated with improved outcomes and less resource utilization. 8 Studies comparing LOS and discharge disposition after TAVR versus SAVR remain sparse. The present study aims to assess the effect of TAVR, compared with SAVR, on hospital LOS and discharge disposition using a large, nationally representative database.
METHODS

Study Design and Population
The data, analytic methods, and study materials will not be made available to other researchers for purposes of reproducing the results or replicating the procedure. Hospitalizations for TAVR and SAVR were identified using the National Inpatient Sample (NIS) database. The NIS is the largest publically available all-payer health care database in the United States and includes >7 million hospitalizations from 1000 hospitals each year, representing a 20% stratified sample of all hospitals in the United States. 9 In 2012, the NIS redesigned the sampling strategy from a 20% stratified sample of hospitals to a 20% stratified random sample of discharges. The International Classification of Disease, Ninth Revision, Clinical Modification (ICD-9-CM) diagnostic and procedural codes were used to identify eligible patients. This study was considered exempt from institutional review board approval because Healthcare Cost and Utilization Project-NIS contain deidentified patient information.
Adults aged ≥50, with aortic stenosis (ICD-9-CM 424.1) and undergoing either elective TAVR (35.05 and 35.06) or elective SAVR (35. 21 and 35.22) between January 1, 2012 and September 30, 2015 (after which ICD-10 codes were implemented) were eligible for inclusion. Patients diagnosed with congenital aortic disorders (746.3), rheumatic aortic stenosis (395.0-395.9), or hypertrophic obstructive cardiomyopathy (425.11) or who underwent additional vascular procedures (00.61-00.69 and 36.00-36.99), such as coronary artery bypass grafting were excluded. Additionally, patients who underwent surgery >2 days after admission (to limit the analysis to elective AVRs), were discharged against medical advice, had unknown discharge status, or underwent SAVR at a hospital that did not perform at least 1 TAVR procedure that year were also excluded.
The primary outcomes of interest were LOS and discharge disposition. Disposition was categorized as (1) routine/home healthcare, (2) transfer to short-term hospital, (3) transfer to skilled nursing facility (SNF), intermediate care facility, or other care facility, and (4) died.
Statistical Analysis
Differences in the distributions of demographics and hospital characteristics across surgical procedure were compared using χ 2 and Student t tests as appropriate. A P value <0.05 was considered statistically significant. LOS after surgery and discharge disposition were assessed using the same methods. Among patients treated at hospitals, which performed TAVR, the yearly rate of TAVR procedures per 100 patients undergoing AVR was estimated using Poisson regression. Changes in the rate of TAVR over time were assessed using a likelihood ratio test. NIS sampling weights were not used in this analysis because we were not interested in national estimates of AVR.
Linear regression was used to estimate the change in average LOS and generalized logistic regression was used to estimate
WHAT IS KNOWN
• Bundled fixed payment system has emerged at the forefront to combat rising health care costs.
• Home discharge and shorter length of stay after valve surgery have been associated with less resource utilization and better outcomes.
• Resource utilization will become increasing important in the management of patients after aortic valve replacement, especially in this time of constrained health care resources.
• Therefore, it is crucial to compare how transcatheter aortic valve replacement (TAVR) compares with surgical AVR with respect to length of stay and discharge disposition after valve replacement.
WHAT THE STUDY ADDS
• From 2012 to 2015, the average length of stay after TAVR and surgical AVR declined; but a more significant decline was observed among TAVR patients.
• Discharge disposition after surgical AVR was largely unchanged, but an increase in home discharges and a decline in discharges to skilled nursing facilities were noted for TAVR between 2012 and 2015.
• Patients who underwent TAVR, compared with if they had undergone surgical AVR, had significantly shorter lengths of stay and a higher likelihood of being discharged to home/home healthcare.
the odds of disposition after TAVR versus SAVR. To account for potential confounding, propensity scores (PS) were calculated for each patient. Briefly, the propensity (ie, the probability) of each patient for undergoing TAVR versus SAVR was estimated using discharge year, age, sex, race/ethnicity, Charlson Comorbidity Index (CCI) score, primary insurance type, income, hospital region, hospital type, and hospital size. 10 The Charlson comorbidity score was calculated using the Deyo et al 11 coding scheme. Both age and CCI were modeled as restricted cubic splines to allow for the most flexibility and fewest assumptions when modeling the continuous variables. Trimming at the 1% and 99% cut points was performed to remove nonoverlapping regions. 10 This is done because patients in the nonoverlapping regions represent TAVR patients who always undergo TAVR (always treated) and SAVR patients who always undergo SAVR (never treated) and are not at risk for undergoing the other procedure. SAVR patients with missing data for any of the above variables were unable to have a PS estimated and were, therefore, excluded from weighted analyses.
A standardized morbidity ratio (SMR) weight was then calculated for each patient, where patients undergoing TAVR were assigned a weight of 1, and patients undergoing SAVR were weighed using PS/(1-PS). SMR weights standardize the distribution of measured patient and hospital characteristics in SAVR patients to the distribution seen in TAVR patients, as opposed to inverse probability of treatment weights, which would standardize both the TAVR and SAVR patients to the distribution seen in the total AVR population. SMR weights were selected to ensure that the effect of TAVR was assessed only among highrisk patients (ie, those eligible to undergo TAVR during the time period), without needing to measure risk level directly. As such, SMR-weighted linear and generalized logistic regression were then conducted to estimate the average effect of TAVR among those undergoing TAVR (ie, effect of treatment in the treated). Standardized models were also used to assess the effects of transapical TAVR (35.06) and endovascular TAVR (35.05), compared with SAVR, among patients who had undergone TAVR. Endovascular TAVR included all nontransapical TAVRs.
CIs for both the crude and standardized models were calculated using nonparametric bootstraps. Specifically, 500 resamples with replacement were conducted, and the 95% CIs were calculated using the estimated SD from the resamples. Bootstrapping was used to account for the SMR weighting in the standardized models and ensure that unbiased estimates of the SDs were obtained.
All analyses were performed using SAS 9.4 (SAS Inc, Cary, NC). Figure 1 . Although TAVR patients had higher CCI scores compared with SAVR patients (2.7 versus 1.5; P<0.0001), no significant difference was seen over time (P=0.89), Figure 2 . Additionally, CCI scores remained relatively consistent over time for both TAVR and SAVR patients (P=0.94). The median LOS after valve replacement over the study period was 4 days (interquartile range, 3-6) for TAVR and 6 days (interquartile range, 5-8) for SAVR (P<0.0001). Although average LOS declined among patients undergoing both TAVR (6.3 days to 4.6 days; P<0.0001) and SAVR (7.5 days to 6.8 days; P<0.0001) between 2012 and 2015, there was significantly greater reduction in LOS among TAVR patients (P<0.0001), Figure 3 .
RESULTS
In
Overall, among TAVR patients, 72% were discharged to home/home healthcare, 1% were transferred to short-term hospital, 25% were transferred to skilled nursing facilities, and 3% died. Among SAVR patients, 78% were discharged to home/home healthcare, 1% were transferred to short-term hospital, 20% were transferred to skilled nursing facilities, and 1% died. Between 2012 and 2015, the discharge distribution significantly changed for TAVR patients, with more patients being discharged to home/home healthcare (67.7%-77.4%, P<0.0001), fewer being transferred to skilled nursing facilities (27.1%-20.7%; P<0.0001), and lower in-hospital mortality (4.2%-1.6%; P<0.0001) Figure 4A . Among SAVR patients, no significant differences were seen in discharges to home/home healthcare (76.8%-79.5%; P=0.25) or in-hospital mortality (1.5%-1.3%; P=0.45) during this period, Figure 4B . A small decrease in transfers to skilled nursing facilities was seen (20.9%-18.7%; P=0.01).
After SMR weighting and trimming, 2098 TAVR patients (28.9%) and 2894 SAVR patients (26.7%) were removed, Table I in the Data Supplement. These patients represent TAVR patients who always undergo TAVR (always treated) and SAVR patients who always undergo SAVR (never treated) and are, therefore, not at risk for undergoing the other procedure. No clinically meaningful or statistically significant differences in patient or hospital characteristics were seen between TAVR and SAVR patients after weighting, Table II in the Data Supplement. After standardizing, TAVR patients were significantly less likely to be transferred to SNF (odds ratio [OR], 0.45; 95% CI, 0.40-0.51) and had a significantly lower LOS (change in estimate, −2.93; 95% CI, −3.26 to −2.60), compared with if they had undergone SAVR. There was no significant difference in the incidence of in-hospital mortality after standardization (OR, 0.85; 95% CI, 0.61-1.20), Table 2 .
In standardized models stratified by TAVR access, patients who underwent TAVR via an endovascular approach were significantly less likely to be transferred to SNF (OR, 0.39; 95% CI, 0.34-0.44) and had a significantly lower average LOS (change in estimate, −3.38; 95% CI, −3.72 to −3.05), compared with if they had undergone SAVR. There was no significant difference in the incidence of in-hospital mortality after standardization (OR, 0.72; 95% CI, 0.50-1.03), Table 3 . However, transapical TAVR patients had a similar incidence of discharge to SNF (OR, 0.87; 95% CI, 0.73-1.03), slightly shorter average LOS (change in estimate, −0.60; 95% CI, −1.10 to −0.10) and a higher in-hospital mortality after standardization (OR, 1.75; 95% CI, 1.11-2.78), as compared with if they had undergone SAVR.
DISCUSSION
Our analysis of the NIS database demonstrated that between 2012 and 2015, the proportion of valve replacement by the transcatheter method in TAVRperforming hospitals has steadily risen since it was first approved in the United States. During this time, the average LOS after TAVR and SAVR declined; however, a more significant decline was observed among TAVR patients. Although discharge disposition after SAVR was largely unchanged during this time, we found a significant difference in the discharge disposition after TAVR with an increase in home discharges and a decline in discharges to SNFs between 2012 and 2015. When comparing the 2 procedures, patients who underwent TAVR, compared with if they had undergone SAVR, had significantly shorter LOS and were more likely to be discharged to home/home healthcare, largely driven by patients undergoing TAVR by an endovascular route.
After recent results from the PARTNER 2 and SURTAVI trials, the indication for TAVR has expanded to include those at intermediate surgical risk. 2, 3 With expansion in the scope of TAVR, the proportion of patients undergoing TAVR is expected to increase. From 2012 to 2015, we found an increase in the proportion of patients undergoing TAVR, as compared with isolated SAVR in TAVR-performing hospitals. Our data are largely restricted to the years before TAVR received the intermediate-risk indication. Therefore, we attribute our results to the growing recognition of the success of TAVR among clinicians, increasing availability of this procedure, and rapidly expanding operator experience mainly in inoperable and high surgical risk patients.
Our data demonstrated a significant decrease in LOS post-TAVR from 2012 to 2015, which we think is likely multifactorial. Despite good clinical outcomes, studies in the early TAVR years reported considerably higher costs for TAVR attributed to prolonged recovery period from general anesthesia in frail and elderly patients. 12, 13 Recent reports have found the use of local anesthesia and conscious sedation in TAVR to be associated with reduction in the number of intensive care unit days, as well as fewer postprocedural complications, and a lower early mortality. 13, 14 The annual report from the Society of Thoracic Surgeons/Transcatheter Valve Therapy registry found the use of moderate sedation increased during the time period 2012 to 2015 from 2.2% to 16.6%, supporting our hypothesis. 15 Other possible reasons for decreased LOS are selecting the appropriate patients for early discharge and using smaller sheath sizes, which have been shown to decrease rate of vascular complications.
16
Our study also compared LOS among high surgical risk patients and found a shorter average LOS with TAVR, as opposed to if they had undergone SAVR. This pattern is likely related to higher intraoperative and postoperative complications associated with circulatory support which is required for SAVR and other cardiac surgeries. 17, 18 We speculate that factors such as physical recovery from sternotomy and chest tube placement may also play a role in the longer LOS after SAVR. 19 Conversely, the expanding use of conscious sedation and a trend towards restricting the use of circulatory support in TAVR patients likely impacted the shorter LOS in the TAVR group and are likely to further expand the gap between the LOS after TAVR and SAVR in the future. In addition, the advantages of catheter-based AVR, such as early mobilization time and lower rates of blood loss and acute kidney injury are also likely to play a role as well.
The predictors of discharge disposition after valve surgery and its relation to long-term survival have been previously assessed. In an important study by Henry et al, 8 patients who were discharged to SNF had 2.5× the mortality than those who were discharged home after valve surgery. We restricted our study to TAVRperforming hospitals spanning across years 2012 to 2015 and found patients who underwent TAVR were more likely to be discharged home, as compared with if they had undergone SAVR. Additionally, we saw a trend towards a higher proportion of home discharges when undergoing TAVR for patients during this period of time. The likely reason for the higher percentage of home discharges stems from the shorter LOS associated with TAVR. LOS is a critical factor responsible for in-hospital complications, such as nosocomial infections 20 and deconditioning, 21 which can be a deciding factor in the discharge disposition. Sicker, debilitated patients are more likely to be discharged to nursing facilities. Therefore, higher percentage of home discharges over progressive years is a good sign for the future of TAVR. Additionally, we found no difference in average CCI score, indicating that the improvements in discharge disposition and decrease in average LOS over time among TAVR patients were likely not because of changes in the clinical risk profile of patients. *CIs were estimated using the SD calculated from 500 nonparametric bootstrapping samples. †SMR weights were calculated using admit year, sex, age, race/ethnicity, CCI, primary insurance type, income, hospital region, hospital type, and hospital size; both age and CCI were modeled as restricted cubic splines; weights were trimmed using 1% and 99% cut points.
‡Compared with routine/home healthcare discharge. *SMR weights were calculated using admit year, sex, age, race/ethnicity, CCI, primary insurance type, income, hospital region, hospital type, and hospital size; both age and CCI were modeled as restricted cubic splines; weights were trimmed using 1% and 99% cut points; CIs were estimated using the SD calculated from 500 nonparametric bootstrapping samples.
†Compared with routine/home healthcare discharge.
Transapical access has been associated with increased risk of complications, longer LOS, and slower recovery times and, therefore, has gone out of favor as one of the preferred route of access for TAVR. 22, 23 In our study, more favorable discharge disposition profile for TAVR, as compared with SAVR, was not demonstrated in the transapical cohort and remained restricted to the endovascular cohort; interestingly, we did find that it was associated with slightly shorter average LOS. Furthermore, those with transapical TAVR were found to have higher inpatient mortality, compared with if they had undergone SAVR. This confirms the current paradigm where transfemoral access for TAVR has emerged as the default strategy because of the better adverse effect profile and feasibility to perform TAVR under conscious sedation with the sole use of transthoracic echocardiography. 24, 25 The results of this study are even more applicable today than they were at the time of this study population, as the rate of transapical access has reduced dramatically. 26 This study should be considered in light of some important limitations. Given the nature of the NIS database, we were unable to account for some clinical covariates which effect the association between the interventions. However, the NIS is a large, nationally representative database and by using PS, specifically SMR weighting, we restricted our study to high-risk patients who were eligible for (and underwent) TAVR without having to capture and report risk level. We encourage future TAVR research in large databases to use these statistical methods to remove patients ineligible for TAVR and appropriately account for patient risk level. Second, as the NIS is a deidentified database, long-term outcomes and complications occurring after the initial TAVR hospitalization could not be assessed. We are also unable to determine if this study includes repeated observations of patients who underwent >1 AVR (TAVR or SAVR) during the study period. There was also potential for coding errors and differences in coding practices across the hospitals included in the database. However, we suspect that these differences are random and would not be expected to differ between TAVR and SAVR patients. Last, ICD coding prevents us from being able to differentiate between different endovascular approaches and, therefore, prevents us from comparing outcomes between different endovascular approaches, such as transfemoral, direct aortic, or transaxillary approaches.
CONCLUSIONS
As we move towards a value-based payment system and extend the reach of TAVR to low surgical risk patients, LOS and discharge disposition will play vital roles in the management of patients with severe, symptomatic aortic stenosis, especially in this time of constrained health care resources. From 2012 to 2015, there was a substantial decrease in LOS and an increase in the proportion of home discharges during the same time period among patients undergoing TAVR. In addition, high-risk patients had a significantly shorter LOS when undergoing TAVR, were more likely to be discharged home, and were less likely to be discharged to an SNF, compared with if they had undergone SAVR. The technical advancements in transcatheter technology and growing procedural experience are leading to continued improvements in outcomes with TAVR and a reduction in the use of postoperative healthcare resources.
